peripheral T-cell lymphoma who had become resistant to
or had relapsed on prior therapies. ;is decision was based
on clinical trial results showing that belinostat was e;ective
in more than 25 percent of patients, many of whom had
received numerous prior therapies. It therefore o;ers a
new treatment option for the 7,000 to 10,000 individuals
anticipated to be diagnosed with peripheral T-cell
lymphoma in 2014, most of whom will become resistant to
their initial therapy.

New Option for Blocking Blood Supply to Tumors

Research has shown that many solid tumors are dependent
on the growth of new blood and lymphatic vessels to
grow and survive. It has also led to the identi;cation of
many molecules that control these processes, as well as
the development of anticancer therapies that speci;cally
block these molecules. In fact, in the past 10 years, the
FDA has approved 10 such therapeutics, which are called
antiangiogenic agents (see Figure 12).